Prescription

Tilak Healthcare Strengthens Its Leadership Team

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Human Resources, Optical, Finance, Health, Health Technology, Professional Services, Other Health, Retina, Social Security, Conditional sentence, HEC Paris, Euronext Growth, CFO, Partnership, Knowledge, Health care, Information, University, Prescription, Head, Visual impairment, Laboratory, ParisTech, Drug, Alcon, Social, Genomics, Pharmacy, Directorate, Multimedia, Ministry, Doctorate

Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-founder), Philip Bouchet (Chief Operating and Product Officer), and Dr. Bénigne Mathieu (Chief Business Officer).

Key Points: 
  • Tilak Healthcare, a leading company in digital health for the monitoring of chronic eye diseases, announces the appointment of three experts to support the leadership team, currently composed of Edouard Gasser (CEO & co-founder), Philip Bouchet (Chief Operating and Product Officer), and Dr. Bénigne Mathieu (Chief Business Officer).
  • For Benoît Gueugnon, CFO: "I would like to thank the management team as well as the investors of Tilak Healthcare (iBionext, Elaia, Swen Capital, Matmut, Caphorn, and Laboratoires Théa).
  • For Dr. Patricia Zilliox: "I am impressed by Tilak Healthcare's journey, establishing itself as a leader in digital health in ophthalmology.
  • Undoubtedly, these achievements and the quality of the team are undeniable assets for approaching the American market."

Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations

Retrieved on: 
Monday, March 18, 2024
Class Action Lawsuit, Professional Services, Legal, ALS, Patient, Prescription, Eric Gibbs, Pharmaceutical industry

Gibbs Law Group reminds investors that a lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx Pharmaceuticals”) (NASDAQ: AMLX), on behalf of investors who purchased or acquired shares between November 11, 2022, and November 8, 2023.

Key Points: 
  • Gibbs Law Group reminds investors that a lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx Pharmaceuticals”) (NASDAQ: AMLX), on behalf of investors who purchased or acquired shares between November 11, 2022, and November 8, 2023.
  • Our investigation concerns whether Amylyx Pharmaceuticals has violated federal securities laws by providing false or misleading statements to investors.
  • Biotechnology company Amylyx Pharmaceuticals develops treatments for amyotrophic lateral sclerosis (“ALS”), and other neurodegenerative diseases.
  • Following this announcement, Amylyx Pharmaceuticals shares plummeted over 81% in intraday trading on March 8, 2024, causing significant harm to investors.

AHF Thanks Matsui for Fighting Big PhRMA

Retrieved on: 
Tuesday, March 12, 2024
FDA, Men, Health, Family, Consumer, Congressional News, Views, Healthcare Reform, Public Policy, Government, Pharmaceutical, General Health, Health Insurance, Women, Other Policy Issues, Patient, AHF, AIDS, Congress, AIDS Healthcare Foundation, Prescription

AIDS Healthcare Foundation (AHF) applauds Representative Doris Matsui (D-CA) for her willingness to take on drug companies for their illegal contract pharmacy restrictions.

Key Points: 
  • AIDS Healthcare Foundation (AHF) applauds Representative Doris Matsui (D-CA) for her willingness to take on drug companies for their illegal contract pharmacy restrictions.
  • As a 340B provider, AHF understands how contract pharmacy restrictions not only deny nonprofits vital savings but also interfere with their successful models of care.
  • “Drug companies have done everything possible to reduce the number of prescriptions available at 340B prices,” said Laura Boudreau, AHF Chief of Operations.
  • AHF is proud to support this bill.”
    As 340B finds itself in the crosshairs of drug makers bent on the program’s destruction, the 340B PATIENTS Act will provide the necessary pushback.

CHLA Researchers Find That Length of Opioid Treatment for Hospitalized Infants Differs by Institution and Geography

Retrieved on: 
Tuesday, March 12, 2024
Other Health, Research, Pharmaceutical, Family, Consumer, Hospitals, Children, Science, Surgery, Baby, Maternity, Other Science, Health, JAMA Network Open, Ventricular septal defect, Risk, Infant, Prescription, MD, Methadone, MSHS, Hydromorphone, Morphine, Multimedia, Paper, Policy, Intubation, Fentanyl

View the full release here: https://www.businesswire.com/news/home/20240312681130/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240312681130/en/
    In a study published in JAMA Network Open, researchers at Children’s Hospital Los Angeles found the opioid treatment that critically ill, hospitalized infants received depended on their location.
  • The length of time the infants were prescribed opioids differed by geographic region across the U.S.— the Northeast, South, Midwest or West.
  • “Additionally, prolonged opioid exposure in high-risk hospitalized infants has been implicated in worsening neurodevelopmental outcomes,” Dr. Keane says.
  • During their hospital stay, 76% of infants were prescribed opioids such as fentanyl, morphine and hydromorphone, and about 8% received methadone.

Global Smart Insulin Pens Market 10 Year Forecast Report 2024-2034 - A USD 2.30 Billion Market by 2034 with a 10% CAGR During 2024-2034

Retrieved on: 
Thursday, March 28, 2024
Diabetes, CGM, Sanofi, Eli Lilly, Prevalence, Dexcom, Data analysis, Incidence, Partnership, Insulin, Patient, Continuous glucose monitor, Prescription, Novo Nordisk, Investment, Research report, USD, Pharmaceutical industry

DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.
  • The global smart insulin pens market accounted for USD 0.769 billion in 2023 and is expected to reach at USD 2.30 billion by 2034 with a CAGR of 10.47% during the forecast period 2024-2034.
  • Diabetes, particularly types 1 and 2, is becoming more common, which has increased demand for cutting-edge and effective insulin administration systems like smart insulin pens.
  • Advanced technology like Bluetooth connectivity, smartphone applications, and electronic dose-tracking features are all integrated into smart insulin pens.

Greenway Health and DrFirst Partner to Improve Medication Adherence and Improve Patient Outcomes through Technology

Retrieved on: 
Wednesday, March 27, 2024
Research, Greenway Health, KLAS, Partnership, Health, Patient, Health information management, Prescription, Overalls, Medicine, Nursing

TAMPA, Fla., March 27, 2024 /PRNewswire/ -- Greenway Health, a leading health information technology services provider, announced its strategic partnership with health technology pioneer DrFirst to use the power of automation technology to reduce prescription abandonment and improve medication adherence.

Key Points: 
  • TAMPA, Fla., March 27, 2024 /PRNewswire/ -- Greenway Health, a leading health information technology services provider, announced its strategic partnership with health technology pioneer DrFirst to use the power of automation technology to reduce prescription abandonment and improve medication adherence.
  • These tools are designed to remove barriers for patients and improve adherence to the prescribed medication.
  • "Our mission at Greenway Health is to harness the power of technology to evolve the healthcare landscape, enabling successful providers, empowering patients, and building healthier communities," says David Cohen, chief product and technology officer at Greenway Health.
  • Greenway Health is a leading health information technology service provider specializing in electronic health records with its flagship Intergy and Prime Suite products.

MediPharm Labs Reports Fourth Quarter and Full Year Results

Retrieved on: 
Wednesday, March 27, 2024
OPEX, Brazilian Health Regulatory Agency, CFO, International, Webcast, Patient, VIVO, Research, Good manufacturing practice, Acquisition, Prescription, ANVISA, GMP, Adjustment, TSX, Cannabis, Good, THC, Marketing, Fine chemical

TORONTO, March 27, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.

Key Points: 
  • TORONTO, March 27, 2024 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.
  • MediPharm has two medical cannabis products with ANVISA authorizations and will increase deliveries to a new pharma partner in 2024.
  • David Pidduck, CEO, MediPharm Labs commented, "MediPharm now has the margins, Opex and Adjusted EBITDA results all trending in the right direction.
  • We are proud of the work completed in 2023 and excited about the future of MediPharm Labs."

Optavise Annual Benefits Broker Survey Shows Regulatory and Compliance Factors Driving Employers' Engagement with Brokers

Retrieved on: 
Wednesday, March 20, 2024
Hospice and palliative medicine, Communication, Partnership, Prescription, Insurance, Disease, Traction, ID, Buckey, Private law, Ageing

CARMEL, Ind., March 20, 2024 /PRNewswire/ -- Optavise, a one-stop-shop for employee benefits programs, combining voluntary benefits products and services, technology and expert guidance, today released its 2024 Annual Benefits Broker Report, "Government Mandates Take Center Stage: Unveiling the Dominant Market Force for Benefits Brokers."

Key Points: 
  • Optavise surveyed 70 U.S.-based health insurance brokers, representing the top 15 brokerage firms, for the report.
  • Among the key highlights:
    69% of brokers cite ever-changing federal and state mandates as a leading market force driving their firms to add new products and service offerings.
  • 94% of brokers report high or moderate reliance by their employer clients for compliance and reporting related to their healthcare benefits.
  • Many of these issues can have a direct impact on employee satisfaction and engagement, and employers are increasingly looking toward brokers for support."

Collaboration with Ophelia Provides Highmark Wholecare Members Collaboration With Access to Opioid Use Disorder Treatment

Retrieved on: 
Wednesday, March 20, 2024
Psychiatry, Addiction medicine, Education, Patient, MAT, OUD, Travel, Buprenorphine, Prescription, Death, Opioid use disorder, Methadone, Drug, CDC, Medicaid, Medicare, Food, Fentanyl, Pharmaceutical industry

Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.

Key Points: 
  • Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.
  • In addition to treatment deserts and localized provider shortages, people with OUD tend to experience financial hurdles when seeking treatment.
  • "Highmark Wholecare's collaboration with Ophelia is helping course correct this crisis by providing access to comprehensive OUD care that our Medicaid and D-SNP members can receive quickly and safely."
  • "Our expanded collaboration with Highmark Health through Highmark Wholecare members allows us to serve communities that continue to be severely impacted by the opioid epidemic," said Zack Gray , CEO and co-founder at Ophelia.

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal

Retrieved on: 
Wednesday, March 20, 2024
California Department, Hormone, SAN, Lactic acid, Prescription, Medicaid, OTCQB, FDA, Citric acid, Medi-Cal, Birth control

SAN DIEGO, March 20, 2024 /PRNewswire/ -- Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that it has successfully renegotiated the rebate for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program.

Key Points: 
  • Phexxi is the first and only locally-acting contraceptive gel approved by the FDA.
  • It is applied zero-to-60 minutes before intercourse and works, without hormones, by maintaining the natural vaginal biome with a pH that is naturally inhospitable to sperm.
  • The renegotiated rebate improves Evofem's rebate on Medi-Cal prescriptions by 7.4%, while affording price protection to Medi-Cal against future Phexxi WAC increases.
  • Medi-Cal beneficiaries may receive one box of 12 single-use Phexxi applicators per dispensing, and up to three boxes in any 75-day period.